A
Alfonso Illiano
Researcher at University of Naples Federico II
Publications - 22
Citations - 6012
Alfonso Illiano is an academic researcher from University of Naples Federico II. The author has contributed to research in topics: Lung cancer & Gemcitabine. The author has an hindex of 14, co-authored 22 publications receiving 5361 citations. Previous affiliations of Alfonso Illiano include University of Cagliari.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Gemcitabine Plus Vinorelbine Compared With Cisplatin Plus Vinorelbine or Cisplatin Plus Gemcitabine for Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group
Cesare Gridelli,Ciro Gallo,Frances A. Shepherd,Alfonso Illiano,Francovito Piantedosi,Sergio Federico Robbiati,Luigi Manzione,Santi Barbera,Luciano Frontini,Enzo Veltri,B. Findlay,S. Cigolari,Robert P. Myers,Giovanni Pietro Ianniello,Vittorio Gebbia,Giampietro Gasparini,Sergio Fava,Vera Hirsh,Andrea Bezjak,Lesley Seymour,Francesco Perrone +20 more
TL;DR: GlobalQoL is not improved with GemVin, although advantages in some components of QoL were apparent, and Gem Vin could be offered to advanced NSCLC patients who express concern about toxicity.
Journal ArticleDOI
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials.
Massimo Di Maio,Cesare Gridelli,Ciro Gallo,Frances A. Shepherd,Franco Vito Piantedosi,S. Cigolari,Luigi Manzione,Alfonso Illiano,Santi Barbera,Sergio Federico Robbiati,Luciano Frontini,E. Piazza,Giovanni Pietro Ianniello,Enzo Veltri,Federico Castiglione,Francesco Rosetti,Vittorio Gebbia,Lesley Seymour,Paolo Chiodini,Francesco Perrone +19 more
TL;DR: Neutropenia during chemotherapy is associated with increased survival of patients with advanced non-small-cell lung cancer, and its absence might be a result of underdosing.
Journal ArticleDOI
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study
Cesare Gridelli,Ciro Gallo,M. Di Maio,Emiddio Barletta,Alfonso Illiano,Paolo Maione,Stefania Salvagni,Francovito Piantedosi,Giovanni Palazzolo,Orazio Caffo,Anna Ceribelli,Alfredo Falcone,P Mazzanti,L. Brancaccio,M A Capuano,L. Isa,Santi Barbera,Francesco Perrone +17 more
TL;DR: The weekly schedule could be preferred for patients candidate to receive docetaxel as second-line treatment for advanced NSCLC, because of some QoL advantages, lower toxicity and no evidence of strikingly different effect on survival.
Journal ArticleDOI
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer
Lucio Crinò,Giuseppe Bronte,Paolo Bidoli,Paola Cravero,Elisa Minenza,Enrico Cortesi,Marina Chiara Garassino,Claudia Proto,Federico Cappuzzo,Francesco Grossi,Giuseppe Tonini,Maria Giuseppina Sarobba,Graziella Pinotti,Gianmauro Numico,Riccardo Samaritani,Libero Ciuffreda,Antonio Frassoldati,Marco Bregni,Antonio Santo,Francovito Piantedosi,Alfonso Illiano,Filippo de Marinis,Stefano Tamberi,Diana Giannarelli,Angelo Delmonte +24 more
TL;DR: It is confirmed that nivolumab is active in non-squamous NSCLC patients with brain metastases, despite their poor prognosis, and its safety profile is concordant with results in the EAP overall population and in patients with other malignancies.